



Sources
PhRMA, “Medicines in Development 2020 Update: Cell and Gene Therapy” (2020).
Beacon Targeted Therapies, “Our Highlights from CAR-TCR Europe 2020) (2020).
False
Intel shows a rise in cell and gene therapy development in the US, with China not far behind




Sources
PhRMA, “Medicines in Development 2020 Update: Cell and Gene Therapy” (2020).
Beacon Targeted Therapies, “Our Highlights from CAR-TCR Europe 2020) (2020).
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.
False
False
August 13, 2025
1 min read
From standardizing CAR-T manufacturing to blockchain-backed data sharing, this roundtable tackles what it takes to scale life-saving advanced therapies.
August 12, 2025
5 min read
Academic medical centers are racing to adapt as political turnover and funding uncertainty threaten the future of cell and gene therapy research.
August 11, 2025
2 min read
The trial will continue, but development activities associated with a monoclonal antibody are to be discontinued
August 4, 2025
5 min read
FDA investigations, shipments holds, a resignation at the FDA and a negative opinion in Europe… I look into the recent controversy
False
Affiliations:
Specialties:
Areas of Expertise: